NCT06484361 2024-07-03
PET/MRI to Stage Prostate Cancer Patients
IRCCS San Raffaele
Phase 2 Recruiting
Clinical Trials
11 trialsNCT04264208 2024-02-01
HDR Brachytherapy 68-Ga-RM2 PET, 68-Ga-PSMA-11 PET &Multi Parametric MRI in Prostate Cancer
Stanford University
Phase 2 Terminated
NCT03949517 2024-01-30
68-Ga PSMA 11 PET/MRI and 68-Ga RM2 PET/MRI for Evaluation of Prostate Cancer Response to HIFU Therapy
Stanford University
Phase 1/2 Completed
NCT03831711 2023-12-13
68-Ga-RM2 PET/MRI in Imaging Patients With Estrogen Receptor-Positive Breast Cancer
Stanford University
Phase 1/2 Completed
NCT03113617 2023-12-12
68Ga-RM2 PET/CT in Detecting Regional Nodal and Distant Metastases in Patients With Intermediate or High-Risk Prostate Cancer
Stanford University
Phase 2 Completed
NCT02624518 2023-04-10
68Ga-RM2 PET/MRI in Biochemically Recurrent Prostate Cancer
Stanford University
Phase 2/3 Completed
NCT02559115 2021-05-18
68Ga-RM2 for PET/CT of Gastrin Releasing Peptide Receptor (GRPr) Expression in Prostate Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT03731026 2018-11-06
The LightPath® and 68Ga-RM2 in Breast Cancer Study
Lightpoint Medical Limited
Phase 3 Unknown
NCT02440308 2017-04-11
68Ga-DOTA-Bombesin PET/MRI in Imaging Patients With Prostate Cancer
Stanford University
Phase 2 Completed
NCT02483884 2017-03-22
PET/CT Imaging Study of the Safety and Diagnostic Performance of [68Ga]RM2 in Patients With Primary Prostate Cancer
Life Molecular Imaging SA
Phase 1/2 Terminated
NCT01205321 2013-01-21
PET/CT Imaging for Radiation Dosimetry, Plasma Pharmacokinetics, Biodistribution, Safety and Tolerability and Diagnostic Performance of BAY86-7548 in Patients With Prostate Cancer and Healthy Volunteers
Life Molecular Imaging SA
Phase 1 Completed